Early-stage Prostate Cancer Rates Continued to Decline After Task Force Recommendations

Early-stage Prostate Cancer Rates Continued to Decline After Task Force Recommendations
The rates of PSA screening and early-stage prostate cancer incidence declined through 2013 following a U.S. Preventive Services Task Force (USPSTF) recommendation against routine PSA (prostate specific antigen) screening in primary care. The study, Prostate Cancer Incidence Rates 2 Years After the US Preventive Services Task Force Recommendations Against Screening," was published in Jama Oncology. In 2011, recommendations against the routine use of PSA testing in all men were established by the task force. A notable decline in the incidence of early-stage prostate cancer was reported from 2011 to 2012. Now, researchers found that the number of detected cases declined even further through 2013. "Whether this pattern will lead to a future increase in the diagnosis of distant-stage disease and prostate cancer mortality requires long-term monitoring because of the slow-growing nature of this malignant neoplasm," study author Ahmedin Jemal, DVM, PhD, vice president of surveillance and health services research at the American Cancer Society, and his colleagues wrote in the report. The team used SEER (Surveillance, Epidemiology, and End Results) registries of the National Cancer Institute – representing around 28 percent of the U.S population – to evaluate the incidence of early-stage prostate cancer. The results showed a continued decline from 2012 to 2013 in men 50 years or older, although not to the same extent as the year before. According to USPSTF, the lifetime risk of being affected with prostate cancer is currently estimated at 16 percent, with the ma
Subscribe or to access all post and page content.
Alexandra holds a BSc in psychology with continued studies in neuroscience and pharmacology. She also holds an interdisciplinary Med. Licentiate, merging the fields of neuropharmacology, psychiatry and immunology from the Karolinska Institute, Stockholm, Sweden. Her previous research focused on interaction between the immune- and neurotransmitter systems regarding psychotic disorders.

Leave a Comment

Your email address will not be published. Required fields are marked *